ESSEX BIO-TECH (01061) announces its interim performance: a net profit of HKD 163 million for the period, representing a year-on-year increase of 3.79%.
Yisheng Biological Technology (01061) announced its interim performance for the six months ending June 30, 2025, with a revenue of 8...
Essex Bio-Tech (01061) announced its interim performance for the six months ending June 30, 2025, with revenue of HK$877 million, a year-on-year increase of 5.79%; net profit for the period was HK$163 million, a year-on-year increase of 3.79%; basic earnings per share were 28.82 HK cents; it plans to pay a interim dividend of HK 7 cents per share.
Related Articles
Shenwan Hongyuan Group (06806): Shenwan Hongyuan Group Securities completes the issuance of 3.9 billion yuan short-term corporate bonds.
WATTS INT'L(02258) has announced its interim performance, with a net profit of 1570.2 million yuan.
.png)
PEGBIO CO-B(02565): Zou Xinglong has been appointed as Co-Secretary of the Company, authorized representative and legal process agent.
Shenwan Hongyuan Group (06806): Shenwan Hongyuan Group Securities completes the issuance of 3.9 billion yuan short-term corporate bonds.
WATTS INT'L(02258) has announced its interim performance, with a net profit of 1570.2 million yuan.
PEGBIO CO-B(02565): Zou Xinglong has been appointed as Co-Secretary of the Company, authorized representative and legal process agent.
RECOMMEND
Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
26/08/2025
U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
26/08/2025
Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
26/08/2025
